RECRUITING

Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use

Talk to us

Conditions

Type 1 Diabetescontinuous glucose monitor

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a study to develop and evaluate a peer mentoring intervention for Black and Latinx adolescents with type 1 diabetes to increase the initiation and maintenance of a continuous glucose monitoring (CGM) device. This device is a standard of care to improve diabetes management related to diet, exercise, and insulin. Use of CGM has been shown to improve health outcomes, but is not used by adolescents of color. Peer mentors may help improve usage.

Official Title

Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use

Quick Facts

Study Start:2024-05-21
Study Completion:2027-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06171412

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:13 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of type 1 diabetes, as determined clinically by the presence of ketosis or ketoacidosis at presentation and/or the presence of at least one diabetes-related auto-antibody
  2. * Self-identification as Black and/or Latinx.
  3. * Ability of participant to comprehend and communicate in written and spoken English, in order to complete surveys and participate in mentioning sessions and other interview (parents/caregivers do not need to have English fluency)
  4. * Access to personal cellphone or tablet to participate in remote video sessions with the peer mentor
  5. * Naïve to or not currently using CGM. "Current" use is defined as any CGM used for clinical management of T1D for \> 1 week within the last three months.
  1. * Participants with a prior severe skin reaction to CGM sensor or adhesive.
  2. * Current use of CGM
  3. * Current or planned pregnancy
  4. * Inability to comprehend or communicate in spoken/written English
  5. * Subjects with other medical or mental health conditions that would, in the opinion of the investigators, interfere with the conduct of the study or present additional risk to the individual.

Contacts and Locations

Study Contact

Stuart A Weinzimer, MD
CONTACT
877.925.3637
stuart.weinzimer@yale.edu
Robin Whittemore, PhD, APRN, FAAN
CONTACT
203-737-2351
robin.whittemore@yale.edu

Principal Investigator

Robin Whittemore, PhD, APRN, FAAN
PRINCIPAL_INVESTIGATOR
Yale School of Nursing
Stuart A Weinzimer, MD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Yale Children's Diabetes Clinic
New Haven, Connecticut, 06520
United States

Collaborators and Investigators

Sponsor: Yale University

  • Robin Whittemore, PhD, APRN, FAAN, PRINCIPAL_INVESTIGATOR, Yale School of Nursing
  • Stuart A Weinzimer, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-21
Study Completion Date2027-02

Study Record Updates

Study Start Date2024-05-21
Study Completion Date2027-02

Terms related to this study

Keywords Provided by Researchers

  • continuous glucose monitor

Additional Relevant MeSH Terms

  • Type 1 Diabetes